Xofluza, the brand name for baloxavir marboxil, is currently protected by patents. The exact timing of its generic availability depends on several factors, including patent expiry dates and any potential patent challenges.
How long does Xofluza's patent protection last?
Xofluza was approved by the U.S. Food and Drug Administration in October 2018. Drug patents typically provide market exclusivity for a period of 20 years from the filing date of the patent application. However, the actual date when a generic version can enter the market can be influenced by patent extensions, such as those granted under the Hatch-Waxman Act for time lost during the FDA review process, and the outcome of any legal challenges to the patents. For specific details on Xofluza's patent landscape and anticipated generic entry dates, resources like DrugPatentWatch.com can provide up-to-date information [1].
What happens if Xofluza's patents are challenged?
Patent litigation can significantly impact the generic market entry timeline. If generic manufacturers file an Abbreviated New Drug Application (ANDA) and challenge the validity or infringement of Xofluza's patents, this can lead to legal battles. The outcome of these lawsuits, including any court rulings or settlement agreements, will determine when generic versions of Xofluza can be legally marketed in the United States.
Who manufactures Xofluza?
Xofluza is developed and marketed by Shionogi Inc. and its partner Roche [2].
When does Xofluza's exclusivity expire?
Exclusivity for Xofluza is tied to its patent protections. While the initial patent term is 20 years from the filing date, extensions and potential legal challenges can alter the precise date of market exclusivity expiry. Consulting patent databases or specialized pharmaceutical intelligence services is recommended for the most current information regarding exclusivity periods.
What is the mechanism of action for Xofluza?
Xofluza is an antiviral medication that works by inhibiting the cap-dependent endonuclease activity of the influenza virus's polymerase acidic protein. This enzyme is crucial for viral gene transcription and replication [3]. By blocking this process, Xofluza helps to stop the virus from multiplying within the body.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www. Drugs.com/brands/xofluza.html
[3] https://www. Aidsinfo.nih.gov/drugs/1560/baloxavir-marboxil/0/0